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This lecture will take a focussed look at key elements of
the cGMP signalling cascade in vascular cells and recent
advances in our knowledge of cGMP-dependent protein
kinase (cGK or PKG) and its substrate VASP (Vasodilator-
stimulated phosphoprotein) [1]. In particular, the role of
this pathway for the regulation of platelet – vessel wall
interactions will be examined [2,3]. Vasodilator-stimu-
lated phosphoprotein (VASP) belongs to the Ena/VASP
family, which plays an important role in regulating
cytoskeletal dynamics, cell migration and other complex
cellular functions [1,4]. Three VASP phosphorylation sites
have been identified, serine157, serine239, and
threonine278. Serine239 is the preferential phosphoryla-
tion site for PKG, whereas serine157 is the preferential
phosphorylation site for PKA. Recently, we showed that
VASP serine157 is also phosphorylated in vascular
smooth muscle cells (SMCs) in response to growth factors
mediated by PKC. Additional data suggest that VASP
phosphorylation at serine157 is important for the growth-
stimulatory effect of VASP in SMCs, whereas VASP phos-
phorylation at serine239 is involved in the growth inhib-
itory effects of NO on SMCs [5]. Overall, VASP appears to
be a modulator of vascular cell functions by integrating
positive and negative signals that target different phos-
phorylation sites of VASP.
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